L
Laura K. Aguilar
Researcher at Harvard University
Publications - 43
Citations - 1732
Laura K. Aguilar is an academic researcher from Harvard University. The author has contributed to research in topics: Immunotherapy & Prostate cancer. The author has an hindex of 20, co-authored 39 publications receiving 1503 citations. Previous affiliations of Laura K. Aguilar include Baylor College of Medicine & Center for Cell and Gene Therapy.
Papers
More filters
Journal ArticleDOI
Cytotoxic T lymphocyte therapy for epstein-barr virus+ Hodgkin's disease
Catherine M. Bollard,Catherine M. Bollard,Laura K. Aguilar,Karin Straathof,Benedikt Gahn,M. Helen Huls,Alexandra Rousseau,John W. Sixbey,M. Victoria Gresik,George Carrum,George Carrum,Melissa M. Hudson,Dagmar Dilloo,Adrian P. Gee,Adrian P. Gee,Malcolm K. Brenner,Malcolm K. Brenner,Cliona M. Rooney,Cliona M. Rooney,Helen E. Heslop,Helen E. Heslop +20 more
TL;DR: The performance and fate of these human tumor antigen–specific T cells in vivo suggests that they might be of value for the treatment of EBV+ Hodgkin lymphoma.
Journal ArticleDOI
Phase IB Study of Gene-Mediated Cytotoxic Immunotherapy Adjuvant to Up-Front Surgery and Intensive Timing Radiation for Malignant Glioma
E. Antonio Chiocca,Laura K. Aguilar,Susan Bell,Balveen Kaur,Jayson Hardcastle,Robert Cavaliere,John M. McGregor,Simon S. Lo,Abhik Ray-Chaudhuri,Arnab Chakravarti,John C. Grecula,Herbert B. Newton,Kimbra S. Harris,Robert G. Grossman,Todd Trask,David S. Baskin,Carissa Monterroso,Andrea G. Manzanera,Estuardo Aguilar-Cordova,Pamela Z. New +19 more
TL;DR: AdV-tk plus valacyclovir can be safely delivered with surgery and accelerated radiation in newly diagnosed malignant gliomas and MGMT independence trends are encouraging, although not powered for efficacy.
Journal ArticleDOI
Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy.
Silvia Salgado,Jesus Garcia,Jose Vera,Fernando Siller,Miriam Bueno,Alejandra Miranda,Aida Segura,Guillermo Grijalva,Jorge Segura,Héctor Fabio Bermúdez Orozco,Rogelio Hernández-Pando,Mary Fafutis,Laura K. Aguilar,Estuardo Aguilar-Cordova,Juan Armendáriz-Borunda +14 more
TL;DR: In a rat cirrhosis model, a single iv administration of a replication-deficient adenoviral vector encoding a nonsecreted form of human uPA resulted in high production of functional uPA protein in the liver, which led to induction of collagenase expression and reversal of fibrosis with concomitant hepatocyte and improved liver function.
Journal ArticleDOI
Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.
Lee A. Wheeler,Andrea G. Manzanera,Susan Bell,Robert Cavaliere,John M. McGregor,John C. Grecula,Herbert B. Newton,Simon S. Lo,Behnam Badie,Jana Portnow,Bin S. Teh,Todd Trask,David S. Baskin,Pamela Z. New,Laura K. Aguilar,Estuardo Aguilar-Cordova,E. Antonio Chiocca +16 more
TL;DR: Survival outcomes were most notably improved in patients with minimal residual disease after gross total resection, suggesting GMCI can be safely combined with SOC in newly diagnosed malignant gliomas.
Journal ArticleDOI
Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion
Jesús García-Bañuelos,Fernando Siller-López,Alejandra Miranda,Laura K. Aguilar,Estuardo Aguilar-Cordova,Juan Armendáriz-Borunda +5 more
TL;DR: The potential use of adenoviral vectors in safe transient gene therapy strategies for human liver cirrhosis is demonstrated and proof of concept on fibrosis reversion by a ‘therapeutic’ Ad-vector (AdMMP8) carrying a gene coding for a collagen-degrading enzyme is shown.